July 6, 2021 11:37:10
- Drug delivery platform developer Lexaria Bioscience has been testing its patented technology in conjunction with antivirals Remdesivir and Ebastine during the past year to determine the potential for enhancing their effectiveness against the COVID-19 virus
- Early-stage testing has determined Lexaria’s technology — DehydraTECH — did not inhibit Remdesivir and Ebastine in their use against the virus
- DehydraTECH is a technology that helps drugs gain better bioavailability through effective introduction into patients’ bloodstreams
- The DehydraTECH platform has also shown great potential in enhancing hypertension medication and additional trials are ongoing
Pharmaceutical use and bioavailability innovator Lexaria Bioscience (NASDAQ: LEXX) (CSE: LXX)
recently reported it has achieved a major milestone in efficacy testing in combination with antiviral drugs that comprise a significant weapon in the war against COVID-19 infections, enhancing Lexaria’s potential for eventually partnering with a major pharmaceutical company as a drug delivery platform.
Lexaria’s patented DehydraTECH technology strives to make swallowed pharmaceuticals more potent in their bloodstream bioavailability through creation of a select formulation that rivals the efficacy some…
NOTE TO INVESTORS:
The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks
crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire is part of the InvestorBrandNetwork